TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02806297

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Early cholecystectomy with IOC
Description: The intervention will be laparoscopic cholecystectomy with intraoperative cholangiogram (IOC) on admission within 24 hours of presentation regardless of whether pain or tenderness are present or laboratory values are elevated.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Late cholecystectomy with IOC
Description: The control will be laparoscopic cholecystectomy with IOC once the patient has met the following criteria: (a) a score of less than 2 on the Visual Analogue Pain Scale, (b) no tenderness on physical exam, and (c) decreased lipase to either less than half of the peak value or within normal range (73-393 U/L).
Study: NCT04522089

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AdimrSC-2f
Description: AdimrSC-2f is a candidate vaccine against COVID-19 developed by Adimmune Corporation (Adimmune). Using the baculovirus-insect cells expression system, the recombinant receptor binding domain (RBD) of SARS-CoV-2 spike (S) protein is amplified and purified. AdimrSC-2f is formulated in the different dosages of Spike (S) protein without/with aluminum content as adjuvant.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AdimrSC-2f
Description: AdimrSC-2f is a candidate vaccine against COVID-19 developed by Adimmune Corporation (Adimmune). Using the baculovirus-insect cells expression system, the recombinant receptor binding domain (RBD) of SARS-CoV-2 spike (S) protein is amplified and purified. AdimrSC-2f is formulated in the different dosages of Spike (S) protein without/with aluminum content as adjuvant.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AdimrSC-2f
Description: AdimrSC-2f is a candidate vaccine against COVID-19 developed by Adimmune Corporation (Adimmune). Using the baculovirus-insect cells expression system, the recombinant receptor binding domain (RBD) of SARS-CoV-2 spike (S) protein is amplified and purified. AdimrSC-2f is formulated in the different dosages of Spike (S) protein without/with aluminum content as adjuvant.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AdimrSC-2f
Description: AdimrSC-2f is a candidate vaccine against COVID-19 developed by Adimmune Corporation (Adimmune). Using the baculovirus-insect cells expression system, the recombinant receptor binding domain (RBD) of SARS-CoV-2 spike (S) protein is amplified and purified. AdimrSC-2f is formulated in the different dosages of Spike (S) protein without/with aluminum content as adjuvant.
Study: NCT03539055

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dabigatran Etexilate Oral Capsule
Description: Oral use of Dabigatran etexilate for 90 days BID per product labeling for dosage to reduce incidence of device related thrombus after implantation of a Watchman LAA device.
Study: NCT01508871

Intervention type: OTHER
Intervention: Observational study, no intervention
Description: No intervention
Study: NCT02424253

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZPL-3893787
Description: ZPL-3893787

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matched Placebo
Study: NCT01455688

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: early HAART
Description: Initiation of HAART within 5 days of ICU admission

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Late HAART
Description: Initiation of HAART after ICU discharge
Study: NCT03889977

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Resistance exercise
Description: 2 major muscle groups (lower extremity, chest)
Study: NCT02243215

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Access to a portable trainer for laparoscopic skills
Description: Participants will have a portable trainer available to allow training at their convenience, and will be able practice on-site at Center of Clinical Education and at their local hospital.
Study: NCT01886365

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Space GlucoseControl System, B. Braun, Melsungen, Germany
Description: Computerized algorithmic application of insulin

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Space GlucoseControl System, B. Braun, Melsungen, Germany
Description: Computerized algorithmic application of insulin

Intervention type: OTHER
Group type: OTHER
Intervention: Conventional therapy with a fixed insulin dosing scheme
Description: Routine care
Study: NCT00935480

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Isentress®
Description: P.O, 1 tablet containing 400 mg every 12 hours

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Celsentri®
Description: p.o.: 1 tablet containing 150 mg morning and evening (due to combination with PI/r) or containing 300 mg if fosamprenavir/r is used as the PI (MA)
Study: NCT00949546

Intervention type: DRUG
Intervention: etanercept
Description: etanercept 50 mg sc twice weekly
Study: NCT01136655

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 80/2.25 μg Symbicort pMDI
Description: inhalation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 80/2.25 μg Symbicort pMDI
Description: inhalation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 80/4.5 μg Symbicort pMDI
Description: inhalation

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Foradil Aerolizer 12 μg
Description: inhalation

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 40 μg budesonide HFA pMDI
Description: inhalation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 40 μg budesonide HFA pMDI
Description: inhalation

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 40 μg budesonide HFA pMDI
Description: inhalation

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo HFA pMDI
Description: inhalation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo HFA pMDI
Description: inhalation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo HFA pMDI
Description: inhalation
Study: NCT01617980

Intervention type: OTHER
Group type: OTHER
Intervention: Multimodal hypoxia imaging
Description: Patients with inoperable, stage III non-small cell lung cancer receive serial 18F-FMISO dPET-CT and functional MRI investigations prior, during and post radiation treatment
Study: NCT02278900

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Communication aids
Description: Question Prompt list Audiofile
Study: NCT02937818

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab and Tremelimumab
Description: Durvalumab + tremelimumab via intravenous (IV) infusion every 4 weeks (q4w), starting on Week 0, for up to a total of 4 months (4 cycles) followed by durvalumab monotherapy via IV infusion q4w, starting on Week 16 until PD, or for other discontinuation criteria.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD1775 and carboplatin (CBPT)
Description: AZD1775 twice daily (oral) for 2.5 days from Day 1 + CBDP area under the curve 5 (Day1) (IV); every 3 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD6738 and olaparib
Description: AZD6738 once a day (oral) for 7 days from Day 1 + olaparib twice a day(oral) for 28 days from Day 1, every 4 weeks
Study: NCT00768521

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tolterodine tartrate
Description: Part I: tolterodine tartrate 4 mg capsule once a day (qd) for 7 days~Part IIa: tolterodine tartrate 4 mg capsule qd for 7 days~Part IIb: single dose tolterodine tartrate 4 mg capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tolterodine tartrate
Description: Part I: tolterodine tartrate 4 mg capsule once a day (qd) for 7 days~Part IIa: tolterodine tartrate 4 mg capsule qd for 7 days~Part IIb: single dose tolterodine tartrate 4 mg capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tolterodine tartrate
Description: Part I: tolterodine tartrate 4 mg capsule once a day (qd) for 7 days~Part IIa: tolterodine tartrate 4 mg capsule qd for 7 days~Part IIb: single dose tolterodine tartrate 4 mg capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tolterodine tartrate
Description: Part I: tolterodine tartrate 4 mg capsule once a day (qd) for 7 days~Part IIa: tolterodine tartrate 4 mg capsule qd for 7 days~Part IIb: single dose tolterodine tartrate 4 mg capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Comparator: Placebo to tolterodine tartrate
Description: Part I: placebo to tolterodine tartrate 4 mg capsule once a day (qd) for 7 days~Part IIa: placebo to tolterodine tartrate 4 mg capsule qd for 7 days~Part IIb: single dose placebo to tolterodine tartrate 4 mg capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Comparator: Placebo to tolterodine tartrate
Description: Part I: placebo to tolterodine tartrate 4 mg capsule once a day (qd) for 7 days~Part IIa: placebo to tolterodine tartrate 4 mg capsule qd for 7 days~Part IIb: single dose placebo to tolterodine tartrate 4 mg capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Comparator: Placebo to tolterodine tartrate
Description: Part I: placebo to tolterodine tartrate 4 mg capsule once a day (qd) for 7 days~Part IIa: placebo to tolterodine tartrate 4 mg capsule qd for 7 days~Part IIb: single dose placebo to tolterodine tartrate 4 mg capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Comparator: Placebo to tolterodine tartrate
Description: Part I: placebo to tolterodine tartrate 4 mg capsule once a day (qd) for 7 days~Part IIa: placebo to tolterodine tartrate 4 mg capsule qd for 7 days~Part IIb: single dose placebo to tolterodine tartrate 4 mg capsule
Study: NCT02970890

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Portable Pain Away™
Description: Portable Pain Away™ device (manufactured by Multi Radiance Medical, Solon - OH, USA) - placebo or active phototherapy

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Portable Pain Away™
Description: Portable Pain Away™ device (manufactured by Multi Radiance Medical, Solon - OH, USA) - placebo or active phototherapy
Study: NCT02756507

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: video-based transdiagnostic REBT
Description: The video-based transdiagnostic REBT consists of 6 sessions delivered in a group format.

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Wait list
Description: Delayed intervention
Study: NCT00193063

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Description: Trastuzumab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Gemcitabine
Study: NCT02881632

Intervention type: DEVICE
Intervention: Structured Light Plethysmography (SLP) - Pneumscan
Description: Both healthy infants and bronchiolitis infants will have their chest movements monitored using Structured Light Plethysmography (SLP) performed by a device (Thora-3 Di) using a projector and two cameras. A light pattern of black and white squares is projected on the child's chest and the cameras record how the shape of this pattern changes with breathing. A computer converts this information to show how the child's chest moves during breathing.

Intervention type: DEVICE
Intervention: Structured Light Plethysmography (SLP) - Pneumscan
Description: Both healthy infants and bronchiolitis infants will have their chest movements monitored using Structured Light Plethysmography (SLP) performed by a device (Thora-3 Di) using a projector and two cameras. A light pattern of black and white squares is projected on the child's chest and the cameras record how the shape of this pattern changes with breathing. A computer converts this information to show how the child's chest moves during breathing.
Study: NCT02573363

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: Given per standard of care

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mitoxantrone Hydrochloride
Description: Given per standard of care

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Selinexor
Description: Given PO
Study: NCT02228590

Intervention type: DRUG
Group type: OTHER
Intervention: APL-130277
Description: Apomorphine Hydrochloride, Sublingual Thin Film
Study: NCT04012047

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Levcromakalim
Description: To investigate the role of levcromakalim compared with placebo in migraine with aura patients

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: To investigate the role of levcromakalim compared with placebo in migraine with aura patients
Study: NCT02062788

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Oral rehydration solution
Description: Preoperative day #1: able to drink Oral rehydration solution (ORS) freely On day of Surgery: Allowed administration until 2hrs prior to surgery. 8AM patients(the first patients to undergo surgery of the day) are recommended to administer ORS at 5:30AM
Study: NCT00604604

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Peer support
Description: Mothers allocated to the peer support group had access to all of the standard community postpartum services in addition to having received telephone-based support from a peer volunteer (a mother who has previously experienced, and recovered from, postpartum depression and has participated in a 4-hour training session). Telephone contact with a new mother was initiated within 48 to 72 hours of trial enrolment and then as frequently as the dyad deemed necessary; a minimum of four contacts were required.
Study: NCT03519763

Intervention type: DIAGNOSTIC_TEST
Intervention: ultrasound
Description: All the patients will have a transvaginal ultrasound evaluation during the first visit to the clinic to evaluate the presence or not of isthmocele.

Intervention type: DIAGNOSTIC_TEST
Intervention: ultrasound
Description: All the patients will have a transvaginal ultrasound evaluation during the first visit to the clinic to evaluate the presence or not of isthmocele.
Study: NCT02503228

Intervention type: PROCEDURE
Intervention: Standard of care osteochondral and or meniscal allograft transplantation
Description: Standard of care osteochondral and or meniscal allograft transplantation

Intervention type: PROCEDURE
Intervention: Standard of care osteochondral and or meniscal allograft transplantation
Description: Standard of care osteochondral and or meniscal allograft transplantation
Study: NCT02268903

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Diuretics : Furosemide
Description: Furosemide 80mg in one single direct intra venous injection

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo in one single direct intra venous injection
Study: NCT01168648

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Yoga as stress management
Description: Yoga specially designed to reduce stress is practiced for approximately 30 minutes at least three times a week for three months, once in a group session led by a trained yoga instructor and twice or more at home. The yoga techniques used are physical postures or movements, meditation and breathing exercises. Every time they do the techniques, participants fill in a form detailing how they feel before and after and providing information on the experience of doing the exercises.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Yoga as stress management
Description: Yoga specially designed to reduce stress is practiced for approximately 30 minutes at least three times a week for three months, once in a group session led by a trained yoga instructor and twice or more at home. The yoga techniques used are physical postures or movements, meditation and breathing exercises. Every time they do the techniques, participants fill in a form detailing how they feel before and after and providing information on the experience of doing the exercises.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Rest without using any relaxation technique
Description: The participants rest at home at least 30 minutes, at least three times a week for three months and without using any relaxation technique
Study: NCT01579448

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Shanchol™, oral cholera vaccine
Description: This killed, whole cell, bivalent vaccine will be presented as a creamish white suspension. Upon storage, a white sediment and clear supernatant may be observed. The recommended dose (1.5ml) of the vaccine must be administered orally. The primary vaccination schedule consists of two doses given at an interval of two weeks. After vigorous shaking of the vial, 1.5 ml should be poured into the mouth of the recipient, followed by water ad libitum. The vaccine can alternatively be administered with a disposable syringe (without needle) after removing the contents from the vial and squirted into the mouth of the recipient.~Vaccine is administered in 1.5 mL vials by mouth in 2 doses, given 2 weeks apart. The vaccine appears as a creamy white suspension.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Shanchol™, killed, whole cell, bivalent, oral cholera vaccine
Description: This killed, whole cell, bivalent vaccine will be presented as a creamish white suspension. Upon storage, a white sediment and clear supernatant may be observed. The recommended dose (1.5ml) of the vaccine must be administered orally. The primary vaccination schedule consists of two doses given at an interval of two weeks. After vigorous shaking of the vial, 1.5 ml should be poured into the mouth of the recipient, followed by water ad libitum. The vaccine can alternatively be administered with a disposable syringe (without needle) after removing the contents from the vial and squirted into the mouth of the recipient.~Vaccine is administered in 1.5 mL vials by mouth in 2 doses, given 2 weeks apart. The vaccine appears as a creamy white suspension.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: no intervention
Description: No intervention will be given to this arm of past placebo recipients. To ensure that boosting was not due to natural exposure to Vibrio cholera, we will compare subjects in the boosting arm to this no intervention arm.
Study: NCT00542269

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amlodipine
Description: amlodipine 5-10 mg tablets. Patients received amlodipine 5 mg (or 10 mg if they were receiving 10 mg prior to study start). Each dose was to be taken orally with water once daily at approximately 8:00 A.M. with or without food, except on the morning of an office/clinic visit, when the study drug was to be taken at the site after the visit procedures had been completed.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amlodipine
Description: amlodipine 5-10 mg tablets. Patients received amlodipine 5 mg (or 10 mg if they were receiving 10 mg prior to study start). Each dose was to be taken orally with water once daily at approximately 8:00 A.M. with or without food, except on the morning of an office/clinic visit, when the study drug was to be taken at the site after the visit procedures had been completed.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amlodipine
Description: amlodipine 5-10 mg tablets. Patients received amlodipine 5 mg (or 10 mg if they were receiving 10 mg prior to study start). Each dose was to be taken orally with water once daily at approximately 8:00 A.M. with or without food, except on the morning of an office/clinic visit, when the study drug was to be taken at the site after the visit procedures had been completed.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aliskiren
Description: aliskiren 150-300 mg tablets. Each dose was to be taken orally with water once daily at approximately 8:00 A.M. with or without food, except on the morning of an office/clinic visit, when the study drug was to be taken at the site after the visit procedures had been completed.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aliskiren
Description: aliskiren 150-300 mg tablets. Each dose was to be taken orally with water once daily at approximately 8:00 A.M. with or without food, except on the morning of an office/clinic visit, when the study drug was to be taken at the site after the visit procedures had been completed.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ramipril
Description: ramipril 5-10 mg capsules. Each dose was to be taken orally with water once daily at approximately 8:00 A.M. with or without food, except on the morning of an office/clinic visit, when the study drug was to be taken at the site after the visit procedures had been completed.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ramipril
Description: ramipril 5-10 mg capsules. Each dose was to be taken orally with water once daily at approximately 8:00 A.M. with or without food, except on the morning of an office/clinic visit, when the study drug was to be taken at the site after the visit procedures had been completed.
Study: NCT03611192

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Multicomponent exercise
Description: Aerobic exercise: 15\~20 mins Resistance exercise: 15 mins Balance exercise: 15\~20 mins Flexibility exercise: 10 mins

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Home-program exercise
Description: 60 mins exercise
Study: NCT01788254

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Codeine
Description: A single oral low dose of codeine 5 mg and midazolam 1 mg administered as drop, pravastatin 5 mg, talinolol 2.5 mg, and torsemide 0.25 mg provided in capsules will be given together at the same time point (cocktail).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam
Description: A single oral low dose of codeine 5 mg and midazolam 1 mg administered as drop, pravastatin 5 mg, talinolol 2.5 mg, and torsemide 0.25 mg provided in capsules will be given together at the same time point (cocktail).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pravastatin
Description: A single oral low dose of codeine 5 mg and midazolam 1 mg administered as drop, pravastatin 5 mg, talinolol 2.5 mg, and torsemide 0.25 mg provided in capsules will be given together at the same time point (cocktail).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Talinolol
Description: A single oral low dose of codeine 5 mg and midazolam 1 mg administered as drop, pravastatin 5 mg, talinolol 2.5 mg, and torsemide 0.25 mg provided in capsules will be given together at the same time point (cocktail).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: torsemide
Description: A single oral low dose of codeine 5 mg and midazolam 1 mg administered as drop, pravastatin 5 mg, talinolol 2.5 mg, and torsemide 0.25 mg provided in capsules will be given together at the same time point (cocktail).
Study: NCT03357679

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Tracheal intubation
Description: Intubation of the trachea with endotracheal tube

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Tracheal intubation
Description: Intubation of the trachea with endotracheal tube

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Glidescope assisted tracheal intubation
Description: With the use of the Glidescope video laryngoscope, the trachea will be intubated with the endotracheal tube

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Bed up head elevated tracheal intubation
Description: Use of the Macintosh laryngoscope blade size 3